论文部分内容阅读
目的观察茵栀黄口服液联合熊去氧胆酸治疗婴儿肝炎综合征的疗效及安全性。方法选取医院收治的肝炎综合征婴儿60例为研究对象,随机分为观察组和对照组,每组30例。对照组采用常规保肝治疗,观察组在常规治疗的基础上采用茵栀黄口服液联合熊去氧胆酸治疗。观察比较2组临床疗效,治疗前后肝脾消肿情况,治疗前后血清总胆红素(TBil)、总丙氨酸转氨酶(SALT)、天冬氨酸转氨酶(AST)指标变化情况。结果观察组治疗总有效率为90.3%,高于对照组的63.5%(P<0.05)。治疗后,2组TBil、SALT、AST水平较治疗前均降低(P<0.05);观察组各指标水平均低于对照组(P<0.05)。2组均未发生不良反应。结论采用茵桅黄口服液联合熊去氧胆酸治疗婴儿肝炎综合征,在退黄、促进肝收缩、促使酶水平的下降等方面效果满意,无不良反应,值得临床推广应用。
Objective To observe the curative effect and safety of Yinzhihuang Oral Liquid Combined with Ursodeoxycholic Acid in the Treatment of Infantile Hepatitis Syndrome. Methods Sixty infants with hepatitis syndrome admitted to hospital were selected as study subjects and randomly divided into observation group and control group with 30 cases in each group. The control group received conventional hepatoprotective therapy. The observation group was treated with Yinzhihuang oral liquid combined with ursodeoxycholic acid on the basis of routine treatment. The clinical curative effect of the two groups was observed and compared. The changes of liver and spleen were observed before and after treatment. The levels of total bilirubin (TBil), total alanine aminotransferase (SALT) and aspartate aminotransferase (AST) were measured before and after treatment. Results The total effective rate of observation group was 90.3%, higher than 63.5% of control group (P <0.05). After treatment, the levels of TBil, SALT and AST in both groups were lower than those before treatment (P <0.05). The levels of each index in the observation group were lower than those in the control group (P <0.05). No adverse reactions occurred in both groups. Conclusions The Yinmao huang oral liquid combined with ursodeoxycholic acid in the treatment of infantile hepatitis syndrome is satisfactory in the aspects of relieving the liver, promoting the hepatic contraction and decreasing the enzyme level, and has no adverse reactions. It is worthy of clinical application.